If Richard Padzur retires, he would become one of several high-ranking FDA officials who left the agency in 2025.

On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world ...

AGC Biologics is set to expand its Cell Line Development Centre of Excellence through a partnership with ATUM.

Citizen Health has entered a multi-year strategic partnership with UCB for expediting drug development across five rare ...

Patient advocacy and industry bodies welcomed the bill’s backing, though it will now need to be passed in the Senate.

Biotechs in the charter city of Próspera aim to cure ageing, but experts question the feasibility of their goals.

Rare disease research faces complex regulations, small patient populations, and high costs. As traditional incentives wane, ...

Data management in oncology clinical trials features multiple complexities, and choosing the right EDC system is essential.

The World Health Organization (WHO) predicts that fewer than 10% of eligible patients will have access to GLP-1RAs by 2030.

As 2026 approaches, rising complexity, geopolitical pressures and new modalities are reshaping strategy, capacity and CDMO ...

With $1.5 billion in drug sales, the US dominated the CKD-HPT, HP and HK market in 2024, representing 59.7% of 7MM sales.

Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...